Gastric Cancer
Copyright
©2007 Baishideng Publishing Group Co. , Limited. All rights reserved.
World J Gastroenterol. Jun 21, 2007; 13(23): 3189-3198
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3189
Table 1 Antibodies for immunohistochemistry
Antibody Clone Diluent’s proportion Company Gastric phenotypic markers MUC5AC CLH2 1:100 Novocastra, Newcastle, UK MUC6 CLH5 1:50 Novocastra, Newcastle, UK HGM 45M1 1:50 Novocastra, Newcastle, UK Intestinal phenotypic markers MUC2 Ccp58 1:100 Novocastra, Newcastle, UK CDX2 CDX2-88 1:50 BioGenex, San Ramon CA Li-cadherin Clone 141713 1:200 Neomarker, Fremont, CA, USA VILLIN CWWB1 1:200 Novocastra, Newcastle, UK Other antibodies Ki -67 K-2 1:50 Zymed, San Francisco, CA, USA CD44v6 VFF-7 1:50 Zymed , San Francisco, CA, USA E-cadherin 4A2C7 1:50 Zymed , San Francisco, CA, USA β-catenin CAT-5H10 1:30 Zymed , San Francisco, CA, USA
Table 2 Gastric and intestinal phenotypic marker expression in gastric SRC carcinoma
Phenotype Age/Gender MUC2 Li-cadherin CDX2 VILLIN HGM MUC5AC MUC6 G type (n = 17) 1 65/F - - - - + + + 2 60/M - - - - + + - 3 67/F - - - - + + - 4 29/F - - - - + + + 5 66/F - - - - + + + 6 49/M - - - - - + - 7 49/M - - - - + + - 8 69/F - - - - + + - 9 33/F - - - - + + - 10 38/F - - - - - + - 11 35/F - - - - + + - 12 56/M - - - - + + - 13 39/M - - - - - + - 14 70/F - - - - + + - 15 42/M - - - - + + - 16 42.M - - - - - + - 17 66/M - - - - + - - I type (n = 10) 1 63/M + + + - - - - 2 75/M + + + - - - - 3 59/F + + + - - - - 4 60/M + - - - - - - 5 31/F + - - - - - - 6 76/F + - - - - - - 7 73/F + - - + - - - 8 46/F + + - - - - - 9 62/M - + - + - - - 10 41/M - + - - - - - GI type (n = 31) 1 31/M + - - - + + - 2 69/F + - - - + + - 3 61/M + - + - + + + 4 67/M + - - - + + + 5 56/M + + + - + + - 6 47/F + + - - + + - 7 65/M + + - - + + - 8 64/M + - - - + + - 9 63/M + + + - + + - 10 48/F + + - - + + + 11 52/F + - - - + + - 12 65/M + + + - + + - 13 72/M + + - - + + - 14 39/F + + + - + + - 15 36/M + + + + + + - 16 51/M + + - - + + - 17 60/F + + - - + - - 18 46/F + - - - + - - 19 45/F + - - - + - - 20 45/F + - + - + - - 21 55/M + + + - + - - 22 65/F + - - - + - - 23 47/F + - - - + - - 24 60/F + + - - + - - 25 46/F - - + - + + + 26 50/F - + - - + + - 27 54/F - + + - + + - 28 32/M - - - + + + - 29 55/M - + + + + + - 30 38/F - + - - + - - 31 59/M - + - - + - - U type (n = 8) 1 36/M - - - - - - - 2 49/F - - - - - - - 3 39/M - - - - - - - 4 61/F - - - - - - - 5 70/F - - - - - - - 6 67/M - - - - - - - 7 64/M - - - - - - - 8 34/F - - - - - - -
Table 3 Different expression patterns of phenotype markers and Ki67 and β-catenin expression in gastric SRC carcinoma
β-catenin Plasma/Nucleus β-catenin expression Phenotype of gastric SRC carcinomas Number of positive GPM Number of positive IPM Cases Ki67 index > 25% membrane expression G type 17 2 (11.8%) 11 (64.7%) 2 (11.8%) G1 1 0 5 0 3 (60.0%) 0 G2 2 0 9 2 (22.2%) 6 (66.7%) 1 (11.1%) G3 3 0 3 0 2 (66.7%) 1 (33.3%) I type 10 5 (50.0%) 1 (10.0%)b 4 (40.0%) I1 0 1 4 1 (25.0%) 0 1 (25.0%) I2 0 2 3 3 (100%) 0 2 (66.7%) I3 0 3 3 1 (33.3%) 1 (33.3%) 1 (33.3%) GI type 31 15 (48.4%)a 12 (36.4%) 14 (45.2%)a GI1 1 1 6 3 (50.0%) 2 (33.3%) 3 (50.0%) GI2 1 2 3 1 (33.3%) 1 (33.3%) 1 (33.3%) GI3 1 3 1 0 0 1 (100%) GI4 2 1 6 3 (50.0%) 3 (50.0%) 3 (50.0%) GI5 2 2 5 4 (80.0%) 4 (80.0%) 2 (40.0%) GI6 2 3 5 2 (40.0%) 1 (20.0%) 1 (20.0%) GI7 2 4 1 0 0 1 (100%) GI8 3 1 2 1 (50.0%) 1 (50.0%) 1 (50.0%) GI9 3 2 2 1 (50.0%) 0 1 (50.0%) U type 0 0 8 3 (37.5%) 4 (50.0%) 3 (37.5%)
Table 4 Correlation between muc2, cdx2, Li-cadherin, Ki-67 index and clinicopathologic features n (%)
MUC2 expression CDX2 expression Li-cadherin expression Ki-67 index Factors Cases MUC2- (n = 34) MUC2+ (n = 32) P CDX2- (n = 52) CDX2+ (n = 14) P Li-cad- (n = 42) Li-cad+ (n = 24) P ≤ 25% (n = 40) > 25% (n = 26) P Gender Male 32 17 (50.0) 15 (46.9) > 0.05 23 (44.2) 9 (64.3) > 0.05 18 (42.9) 14 (58.3) > 0.05 18 (45.0) 14 (53.8) > 0.05 Female 34 17 (50.0) 17 (53.1) 29 (55.8) 5 (35.7) 24 (57.1) 10 (41.7) 22 (55.0) 12 (46.2) Age (yr) Mean ± SE 66 50.9 ± 2.2 56.0 ± 2.2 > 0.051 53.5 ± 1.9 52.9 ± 3.1 > 0.051 51.9 ± 3.0 54.6 ± 2.6 > 0.051 53.9 ± 2.2 51.0 ± 2.3 > 0.051 Tumor diameter < 5.0 cm 32 23 (67.6) 9 (28.1) 0.001 30 (57.7) 2 (14.3) 0.004 24 (57.1) 8 (33.3) > 0.05 24 (60.0) 8 (30.8) 0.02 ≥ 5.0 cm 34 11 (32.4) 23 (71.9) 22 (42.3) 12 (85.7) 18 (42.9) 16 (66.7) 16 (40.0) 18 (69.2) Depth of wall invasion T1 13 11 (32.4) 2 (6.3) 0.0082 13 (25.0) 0 > 0.05 10 (23.8) 3 (12.5) > 0.05 11 (27.5) 2 (7.7) 0.0482 T2 22 10 (29.4) 12 (37.5) 16 (30.8) 6 (42.9) 15 (35.7) 7 (29.2) 14 (35.0) 8 (30.8) T3 22 10 (29.4) 12 (37.5) 15 (28.8) 7 (50.0) 11 (26.2) 11 (45.8) 10 (25.0) 12 (46.2) T4 9 3 (8.8) 6 (18.8) 8 (15.4) 1 (7.1) 6 (14.3) 3 (12.5) 5 (12.5) 4 (15.4) Lymph node metastasis LN (–) 29 21 (61.8) 8 (25.0) 0.003 25 (48.1) 4 (28.6) > 0.05 20 (47.6) 9 (37.5) > 0.05 22 (55.0) 7 (26.9) 0.025 LN (+) 37 13 (38.2) 24 (75.0) 27 (51.9) 10 (71.4) 22 (52.4) 15 (62.5) 18 (45.0) 19 (70.1) Distant metastasis M0 60 32 (94.1) 28 (87.5) > 0.05 48 (92.3) 12 (85.7) > 0.05 39 (92.9) 21 (87.5) > 0.05 36 (90.0) 24 (92.3) > 0.05 M1 6 2 (5.9) 4 (12.5) 4 (7.7) 2 (14.3) 3 (7.1) 3 (12.5) 4 (10.0) 2 (7.7) Vascular invasion V (–) 40 27 (79.4) 13 (40.6) 0.001 34 (65.4) 6 (42.9) > 0.05 31 (73.8) 9 (37.5) 0.004 28 (70.0) 12 (46.2) > 0.05 V (+) 26 7 (20.6) 19 (59.4) 18 (34.6) 8 (57.1) 11 (26.2) 15 (62.5) 12 (30.0) 14 (53.8) TNM stage I+ II 32 22 (64.7) 10 (31.2) 0.007 27 (51.9) 5 (35.7) > 0.05 21 (50.0) 11 (45.8) > 0.05 24 (60.0) 8 (30.8) 0.02 III + IV 34 12 (35.3) 22 (68.8) 25 (48.1) 9 (64.3) 21 (50.0) 13 (54.2) 16 (40.0) 18 (69.2)
Table 5 Correlation between four phenotypes of gastric SRC carcinoma and clinicopathologic features n (%)
Four phenotypes of gastric SRC carcinoma Factors n G type (n = 17) I type (n = 10) GI type (n = 31) UC type (n = 8) Gender Male 32 8 (47.1) 5 (50.0) 15 (48.4) 4 (50.0) Female 34 9 (52.9) 5 (50.0) 16 (51.6) 4 (50.0) Age (yr) Mean ± SE 66 53.7 ± 2.9 49.1 ± 4.0 54.7 ± 2.5 52.8 ± 4.3 Tumor diameter < 5.0 cm 32 15 (88.2)a 3 (30.0)b 10 (32.3) 4 (50.0) ≥ 5.0 cm 34 2 (11.8)a 7 (70.0)b 21 (67.7) 4 (50.0) Depth of wall invasion T1 13 7 (41.2)c 3 (30.0) 1 (3.2) 2 (25.0) T2 22 5 (29.1)c 2 (20.0) 12 (38.7) 3 (37.5) T3 22 4 (23.5)c 2 (20.0) 13 (41.9) 3 (37.5) T4 9 1 (5.9)c 3 (30.0) 5 (16.1) 0 Lymph node metastasis LN (–) 29 13 (76.5)c 4 (40.0) 8 (25.8) 4 (50.0) LN (+) 37 4 (23.5)c 6 (60.0) 23 (74.2) 4 (50.0) Distant metastasis M0 60 16 (94.1) 8 (80.0) 28 (90.3) 8 (100) M1 6 1 (5.9) 2 (20.0) 3 (9.7) 0 Vascular invasion V (–) 40 15 (88.2)c 7 (70.0) 12 (38.7) 6 (75.0) V (+) 26 2 (11.8)c 3 (30.0) 19 (61.3) 2 (25.0) TNM stage I+ II 32 12 (70.6)d 4 (40.0) 12 (38.7) 4 (50.0) III + IV 34 5 (29.1)d 6 (60.0) 19 (61.3) 4 (50.0) IM IM (–) 46 11 (64.7) 6 (60.0) 23 (74.2) 6 (75.0) IM (+) 20 6 (35.3) 4 (40.0) 8 (25.8) 2 (25.0)